Redeye updates its estimates and valuation following Serstech’s Q3 2025 report. Sales and profitability were better than expected, despite no larger orders being announced beforehand. The company also finalised its planned recruitments, meaning that sales and R&D capabilities are now significantly stronger than a year ago. We also learn that two new devices have been developed and are scheduled for release in Q1 2026. We make only minor changes to our estimates and valuation and look forward to following the effects of recent initiatives in 2026e and beyond.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/